MK 0859

Known as: MK-0859, MK0859 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
01220072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
INTRODUCTION While some cholesteryl ester transfer protein inhibitors have had their clinical study interrupted because of no or… (More)
Is this relevant?
2013
2013
Cholesteryl ester transfer protein inhibitors are an important class of compounds designed to treat hypocholesterolemia and… (More)
Is this relevant?
2011
2011
This report describes the lipid and safety data collected during an off-drug period that followed 8 weeks of treatment with the… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • figure 3
Is this relevant?
2011
2011
A (MK-0859) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) currently undergoing development as… (More)
  • figure 1
Is this relevant?
2010
2010
The pharmacokinetics and metabolism of anacetrapib (MK-0859), a novel cholesteryl ester transfer protein inhibitor, were examined… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2009
Review
2009
PURPOSE OF REVIEW Because high-density lipoprotein cholesterol (HDL-C) levels are inversely related to cardiovascular disease… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND The inhibition of cholesteryl ester transfer protein (CETP) is considered a potential new mechanism for treatment of… (More)
Is this relevant?